Global Granisetron Market Size By Type (Transdermal system, Injection), By Application (Chemotherapy, Post operative), By Region, And Segment Forecasts, 2023 to 2032

The Global Granisetron Market was valued at USD 1.1 billion in 2023 and is projected to reach USD 1.78 billion by 2031, growing at a CAGR of 6.3% during the forecast period from 2023 to 2031. Granisetron, a selective 5-HT3 receptor antagonist, is widely used to prevent and treat nausea and vomiting caused by chemotherapy, radiotherapy, and surgery. Market growth is propelled by the rising incidence of cancer, increasing chemotherapy treatments, and the growing awareness of antiemetic therapies among healthcare providers.

Drivers:

1. Rising Cancer Prevalence and Chemotherapy Procedures:

The increasing global burden of cancer has led to a higher number of patients undergoing chemotherapy, a treatment commonly associated with severe nausea and vomiting. This trend significantly drives the demand for effective antiemetic drugs like granisetron.

2. Technological Advancements in Drug Delivery Systems:

The development of transdermal patches and extended-release injectable formulations of granisetron enhances patient compliance and treatment outcomes, contributing to market expansion.

3. Increased Awareness and Supportive Reimbursement Policies:

Efforts by governments and healthcare organizations to improve awareness regarding nausea management in cancer care and better reimbursement policies for oncology drugs are supporting market growth.

Restraints:

1. Side Effects and Safety Concerns:

Despite its effectiveness, granisetron may cause side effects such as constipation, headache, and QT prolongation. These safety concerns can limit its widespread adoption, especially in sensitive populations.

2. Availability of Alternative Antiemetics:

The market faces competition from other 5-HT3 receptor antagonists and novel antiemetics like palonosetron and aprepitant, which may have longer durations of action or better safety profiles.

Opportunity:

1. Growth Potential in Emerging Economies:

Rapidly improving healthcare infrastructure and rising cancer screening rates in countries like India, China, and Brazil are expected to drive demand for antiemetic drugs, creating lucrative opportunities for granisetron manufacturers.

2. Expansion of Non-Oncology Applications:

Emerging research suggests potential benefits of granisetron in treating conditions such as irritable bowel syndrome (IBS) and postoperative nausea, opening new avenues for product diversification.

Market by System Type Insights:

By formulation type, the injectable granisetron segment held the largest market share in 2023 due to its widespread use in clinical settings for rapid relief of chemotherapy-induced nausea. However, the transdermal patch segment is anticipated to grow at the fastest pace owing to its non-invasive nature, convenience, and growing patient preference for sustained-release options.

Market by End-use Insights:

Hospitals were the largest end-use segment in 2023, accounting for over 50% of the market share. Hospitals serve as primary treatment centers for chemotherapy and surgeries, where granisetron is frequently administered. Meanwhile, the ambulatory surgical centers (ASCs) segment is gaining traction due to the growing trend of outpatient surgeries and the increasing availability of compact antiemetic formulations.

Market by Regional Insights:

North America dominated the global granisetron market in 2023, driven by the region’s advanced oncology treatment infrastructure, high awareness levels, and favorable reimbursement environment. However, the Asia-Pacific region is projected to witness the highest growth during the forecast period, supported by a rising cancer population, growing healthcare investments, and increasing accessibility to quality medications.

Competitive Scenario:

Key players in the global granisetron market include Helsinn Healthcare SA, Kyowa Kirin Co., Ltd., Heron Therapeutics, Inc., Sandoz (Novartis AG), Mylan N.V., Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories, Cipla Ltd., and Sun Pharmaceutical Industries Ltd. These companies focus on product innovation, global market expansion, and regulatory approvals to strengthen their competitive positions.

Scope of Work – Global Granisetron Market

Key Market Developments:

2023: Heron Therapeutics received expanded FDA approval for its sustained-release granisetron injection in pediatric use.

2024: Kyowa Kirin launched a generic granisetron transdermal patch in key European markets.

2025: Dr. Reddy’s Laboratories announced a strategic collaboration to develop orally disintegrating granisetron tablets targeting emerging markets.

FAQs:

1) What is the current market size of the Global Granisetron Market?

The market was valued at USD 1.1 billion in 2023.

2) What is the major growth driver of the Global Granisetron Market?

The major growth driver is the increasing prevalence of cancer and the rising number of chemotherapy treatments requiring effective antiemetic support.

3) Which is the largest region during the forecast period in the Global Granisetron Market?

North America is the largest region, with robust oncology care infrastructure and high awareness.

4) Which segment accounted for the largest market share in the Global Granisetron Market?

The injectable granisetron segment held the largest market share in 2023.

5) Who are the key market players in the Global Granisetron Market?

Key players include Helsinn Healthcare SA, Kyowa Kirin Co., Ltd., Heron Therapeutics, Mylan N.V., and Dr. Reddy’s Laboratories.